NRC Health Q2 FY2026 Earnings Call
With Trent Green (CEO), Shane Harrison (CFO) and Jordan Freeman (Chief Accounting Officer).
For more than 40 years, NRC Health (NASDAQ: NRC) has led the charge in healthcare experience management, humanizing healthcare, and supporting organizations in their understanding of each unique individual.
More about NRC Health
We empower healthcare systems with Human Understanding® by encompassing patient experience surveys, CAHPS, AI-powered analytics, reputation management, and employee engagement. NRC Health’s commitment is to help leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health’s patient-focused approach, unmatched market research, and emphasis on consumer preferences are transforming the healthcare experience, creating strong outcomes for patients and entire healthcare systems. NRC Health is ranked #1 in Healthcare Experience Management in the 2025 Best in KLAS report. Based in Lincoln, NE.
1Prepared remarks3 speakers
Thank you, operator. Welcome to NRC Health's earnings conference call for the second quarter ended June 30th, 2026. I wanted to first let you know that we posted our earnings press release to the investor relations section on our website. On this call today, we have NRC Health CEO, Trent Green, and CFO, Shane Harrison. Today's call will include statements related to the expected future results of our company, which are therefore forward-looking statements. Actual results may differ materially from these…
Thank you, Jordan. Good afternoon, everyone. Thank you for joining us for NRC Health's second quarter 2026 earnings call. Today, I'll begin with an overview of our second quarter performance, discuss the momentum we're seeing across the business, and highlight how we continue to advance the next chapter of the NRC Health story with innovation across our product portfolio. We delivered another strong quarter of execution in the second quarter, reflected in our year-over-year total recurring contract value, or TRCV…
Thank you, Trent, and good afternoon, everyone. I'll take the next few minutes to walk through our Q2 2026 results, provide context on our profitability dynamics as we invest to support our TRCV growth, and give an update on capital allocation, including our dividend and share repurchase activity. Starting with TRCV, we finished the quarter with total recurring contract value of $151.9 million, up 11% year-over-year, reflecting continued strength across our Experience, Market Insights, and The Governance Institute…